Karyopharm Therapeutics | KPTI - Себестоимость





Себестоимость Изменить Дата
AbbVie USD 4.22B 329M 2026-03
Abbott USD 5.94B 642M 2026-06
Amgen USD 1.6B 187M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Eli Lilly USD 3.58B 205M 2026-03
GlaxoSmithKline GBP 1.88B 736M 2026-03
Incyte USD 104.5M 16.68M 2026-03
J&J USD 8B 67M 2026-06
Karyopharm Therapeutics USD 1.48M 35.95M 2025-12
MacroGenics USD 9.53M 585K 2026-03
Merck USD 2.94B 380M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Novartis USD 3.46B 83M 2026-03
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Takeda JPY 560.54B 159.39B 2026-03
TG Therapeutics USD 33.51M 4.63M 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Xencor USD 61.66M 50.95M 2025-06